Teva nabs migraine patch maker NuPathe for $144 million, undoing Endo deal
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical said it agreed to buy migraine therapy maker NuPathe for $144 million in cash plus potential milestones after outbidding an earlier suitor.